Background-Phosphatidylserine-expressing microparticles circulate in blood with a short half-life of Ͻ10 minutes. We tested the role of an endothelium-derived phosphatidylserine-binding opsonin, developmental endothelial locus-1 (Del-1), in the uptake of platelet microparticles. Methods and Results-Cultured human umbilical vein and microvascular endothelial cells avidly engulf BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene)-maleimide-labeled platelet microparticles. Microparticle uptake was inhibited by a monoclonal antibody to Del-1 (Pϭ0.027) and by annexin A5 (Pϭ0.027), abciximab (Pϭ0.027), a monoclonal antibody to integrin ␣V␤3 (Pϭ0.027), and chlorpromazine (Pϭ0.027). These results suggest that Del-1 mediates phosphatidylserine-and integrin-dependent endothelial uptake of microparticles by endocytosis. To assess the in vivo significance, we infused fluorescent platelet microparticles into the inferior vena cava of mice and harvested endothelial cells from the pulmonary and systemic circulation. Compared with their wild-type littermates, Del-1-deficient mice had decreased uptake in endothelial cells in lung (3.07Ϯ1.9 versus 1.09Ϯ1. 
M
icroparticles are submicron-sized vesicles released from cells in response to activation or during apoptosis. 1 Formation of microparticles is accompanied by externalization of phosphatidylserine, which is normally present only in the inner leaflet of the membrane bilayer. In platelets, microparticle formation and phosphatidylserine exposure have been studied extensively. [2] [3] [4] Phosphatidylserine, on activated platelets and platelet microparticles, plays an essential procoagulant role in normal hemostasis by providing a surface for the assembly of enzyme-cofactor complexes. In addition to their hemostatic role, platelet microparticles have been shown to elicit cytokine responses from synovial fibroblasts via interleukin 1, 5 stimulate hematopoietic cells, 6 and transfer platelet-specific receptors to the surface of other cells. 7 Recently, several pathophysiological roles have been identified for microparticles derived from other cells. Monocyte-derived microparticles activate endothelial cells in an interleukin-1␤-dependent manner. 8 Tumor-derived microparticles promote activation of macrophages 9 and induce immune suppression by promoting regulatory T-cell expansion. 10 Furthermore, the recent finding that circulating microparticles carry microRNA 11 raises the possibility that their uptake may modify gene expression in host cells.
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Developmental endothelial locus-1 (Del-1), a 52-kDa glycoprotein (also termed Edil3) is secreted by endothelial cells and is expressed in a developmentally restricted pattern during embryogenesis. 12 In adults, Del-1 is expressed in endothelium and in a subset of macrophages. 13, 14 It consists of 3 epidermal growth factor-like repeats at the amino terminus followed by 2 discoidin I-like domains at the C-terminus. 12 The second epidermal growth factor-like repeat contains the canonical Arg-Gly-Asp (RGD) motif that enables Del-1 to bind integrins ␣V␤3 and ␣V␤5. 15 The discoidin I-like domains mediate its binding to phosphatidylserine. Del-1 can act as a bridging molecule between integrin on endothelial cells and phosphatidylserine-containing microparticles. In addition, Del-1 acts as an inhibitor of leukocyte recruitment, and Del-1-deficient mice have increased inflammatory cell accumulation. 14, 16 Here, we investigated the role of Del-1 as a mediator of clearance of phosphatidylserineexpressing platelet microparticles by endothelium.
Methods

Reagents
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene)-maleimide was purchased from Invitrogen Corp (Carlsbad, CA). Vitronectin was isolated from normal human plasma as described previously. 17 Recombinant annexin A5 was isolated as described previously. 18 Human thrombin was purchased from Hematologic Technologies (Essex Junction, VT). Collagen was purchased from Helena Laboratories (Beaumont, TX). Phycoerythrin-labeled monoclonal antihuman CD144 and polyclonal antibodies to CD63 were obtained from eBioscience (San Diego, CA). A rat monoclonal antibody to mouse CD144 (clone 11D4.1) and phycoerythrin-Cy5-labeled CD42B were purchased from BD Biosciences (San Jose, CA). Electron-coupled dye-labeled CD14 (clone REM052) was from Beckman Coulter (Fullerton, CA). A murine monoclonal antibody to human glycophorin (CD235a) and anti-integrin ␣V␤3 (clone LM609) were obtained from Millipore Corp (Billerica, MA). D345 is a murine monoclonal anti-Del-1 IgG derived from BALB/c mice immunized with human recombinant Del-1. The procedures for fusion, screening of hybrids, cloning, immunoglobulin purification, and class and subclass characterization have been reported in detail elsewhere. 19 Human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells were obtained from ATCC (Manassas, VA). Lipopolysaccharide (LPS) from Escherichia coli 0111:B4, chlorpromazine, and amiloride were from Sigma-Aldrich (St Louis, MO).
Mouse Strains
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The generation of Del-1-deficient mice has been described previously. 16 The Del-1 Ϫ/Ϫ mice were rederived at Baylor College of Medicine (Houston, TX) in C57BL/6 mice and backcrossed 6 times to C57BL/6 background. The Institutional Animal Care and Use Committee of Baylor College of Medicine approved all animal protocols.
Isolation of Recombinant Del-1
The cDNA for Del-1 (OriGene Technologies, Inc, Rockville, MD) was amplified by polymerase chain reaction with the primers D1F 5Ј-TTTGAATTC-GGCA-AAGG-TGAT-ATTT-GTGATCCC-3Ј and D1R 5Ј-GGC-GGCCG-CTTCCT-CCTCTGTGC-AGCC-CAGCAG-3Ј. The amplified fragments were digested with EcoR1 and Not1 and ligated into the plasmid vector pPICZ␣, which contains Myc and His tags at the C-terminal end. Pichia pastoris GS115 strain (Invitrogen) was transformed with the plasmid-containing Del-1 cDNA by electroporation, and the culture supernatants were screened for expression by Western blots with monoclonal anti-Myc antibody (clone MYC1-9E10.2 from ATCC). Recombinant Del-1-expressing clone was expanded, and Del-1 was isolated by affinity chromatography with an Ni-NTA column.
ELISA for Del-1
A sandwich ELISA for Del-1 was developed with D345 as the capture antibody and a polyclonal rabbit antibody to Del-1. The standard curve was linear from 1 to 250 ng/mL Del-1.
Isolation, Characterization, and Labeling of Microparticles and Exosomes
Circulating microparticles from peripheral blood were isolated by differential centrifugation. Blood was drawn from healthy volunteers, after receipt of informed consent as approved by the Committee for Protection of Human Subjects. The blood was immediately transferred to polypropylene tubes, and platelet-rich plasma was obtained by centrifugation at 1000g for 3 minutes at room temperature. The platelet-rich plasma was centrifuged at 5000g for 15 minutes at 4°C to obtain platelet-poor plasma. The platelet-poor plasma was further centrifuged at 20 000g for 20 minutes to sediment the microparticles. The pellet containing microparticles was suspended in modified Tyrode buffer for analysis in a flow cytometer (Coulter FC500, Beckman Coulter) with CXP software. The flow cytometer was calibrated for size with nonfluorescent microspheres (Invitrogen) and with isolated unlabeled platelet microparticles. Particles Ͻ1 m in diameter were gated as microparticles. To isolate platelet microparticles, platelets were washed as described previously 20 and incubated with a combination of thrombin (0.1 U/mL) and collagen (50 g/mL) for 30 minutes and centrifuged at 2000g for 15 minutes. The platelet-free supernatant plasma (as determined by flow cytometry) was centrifuged further at 20 000g for 20 minutes. The pellet containing microparticles was resuspended in HEPES-buffered saline (10 mmol/L HEPES, 0.15 mol/L NaCl, pH 7.5). To exclude a possible contamination with immune complexes, 21 the microparticles were treated with 1% Triton X-100 and reanalyzed. There was Ͼ75% reduction in signal ( Figure  1A ). The microparticles were quantified as described previously. 22 The exosomes were isolated by ultracentrifugation (100 000g for 2 hours, of the 20 000g spin supernatant) as described previously. 23 The microparticles and exosomes were characterized by electron microscopy as described previously. 23 For labeling, the microparticles or the exosomes (80 g/mL) were incubated with BODIPYmaleimide (2.5 mol/L) for 20 minutes and washed twice by centrifugation for 20 minutes at 20 000g for microparticles and at 100 000g for exosomes in HEPES-buffered saline.
Endothelial Uptake of Platelet Microparticles
Glass chamber slides (Laboratory-Tek II chamber slides) were coated with vitronectin (5 g/well) overnight with sterile bicarbonate buffer (0.1 mol/L NaCl, pH 8.6). The slides were washed and HUVECs seeded at 1ϫ10 5 cells/well. After confluence was achieved, the endothelial cell monolayers were washed in medium 199, and BODIPY-labeled platelet microparticles were added to the cells and incubated at 37°C for 30 minutes. After vigorous washing, cells were treated with trypan blue (0.4 mg/mL), washed 3 times in HEPES-buffered saline, fixed in 4% paraformaldehyde, and mounted with an aqueous mounting medium (BioMeda Corp, Foster City, CA) and examined by fluorescence microscopy (Nikon Eclipse TE200 microscope with a 60ϫ/0.6 numeric aperture objective): ex 488 nm and at em , 530 nm for BODIPY.
Flow Cytometric Measurement of Uptake by Endothelial Cells
HUVECs were grown on 24-well plates (Falcon, Becton-Dickinson), and after hey achieved confluence, the cells were washed in serum-free medium and BODIPY-labeled microparticles were added to each well (at a ratio of Ϸ2000 -8000 particles per endothelial cell) and incubated at 37°C for 30 minutes. The wells were washed in medium 199 and the cells detached by incubation with 0.05% trypsin-EDTA. After detachment, trypsin was neutralized with fetal calf serum, and cell-surface fluorescence was quenched with trypan blue (0.4 mg/mL). The cells were washed twice by centrifugation in medium 199, incubated with phycoerythrin-labeled anti-human CD144 (5 g/mL), and analyzed by flow cytometry. The gate for endothelial cells was set on the basis of phycoerythrin fluorescence and forward scattering. HUVECs were incubated with antibodies (20 g/mL), annexin A5 (20 g/mL), amiloride (10 mol/L), 24, 25 or chlorpromazine (30 mol/L) 26 for 30 minutes before the addition of platelet microparticles.
Uptake of Platelet Microparticles by Endothelium In Vivo
BODIPY-labeled platelet microparticles were infused into the inferior vena cava of mice under isoflurane anesthesia. After 5 minutes, the mice were euthanized, and lung endothelial cells were isolated as described by Fehrenbach et al 27 with minor modifications. The abdomen and the thoracic cavities were exposed, and 10 mL of phosphate-buffered saline (0.1 mol/L NaCl, 0.05 mol/L phosphate, pH 7.4) was infused via the right ventricle to perfuse the lung. One milliliter of collagenase (from Clostridium histolyticum; 10 mg/mL; Sigma-Aldrich) solution was instilled into the trachea, and the trachea was tied off. The lungs were subsequently dissected out and incubated with 5 mL of collagenase solution in a 50-mL tube for 30 minutes at 37°C in a water bath. After 30 minutes of incubation, 25 mL of phosphate-buffered saline was added, and the tube was vigorously shaken for 30 seconds; the resulting cell suspension was filtered through a cell strainer (80 mesh). The cell suspensions were centrifuged for 4 minutes at 600g. After removal of the supernatant, the cell pellet was resuspended in 5 mL of medium 199 containing 20% fetal calf serum. Red blood cells were lysed by the addition of 18 mL of distilled water, immediately followed by 5 mL of 4.25% sodium chloride. The cells were washed again in medium 199, incubated with rat monoclonal anti-murine CD144 followed by phycoerythrin-labeled goat anti-rat IgG, and analyzed by flow cytometry as described for HUVECs.
To isolate the endothelial cells from liver and spleen, these organs were isolated within 10 minutes of infusion of microparticles and cut into small pieces, washed, and incubated with collagenase. Singlecell suspensions were made as described for the lung and analyzed by flow cytometry with a monoclonal antibody to murine CD144.
Effect of LPS
Del-1 Ϫ/Ϫ mice and their littermate controls (9 in each group) were given LPS (10 g/g) via the tail vein. After 6 hours, blood was drawn from the retroorbital plexus, and microparticles in mouse plasma were quantified as described previously. 28 
Mouse Model of Thrombosis
In vivo thrombosis was assessed with a ferric chloride-induced injury model in the mouse carotid artery with techniques similar to those described elsewhere. 29 For these experiments, mice were injected with LPS from E coli (5 g/kg IP); 4 hours later, they were anesthetized with an intraperitoneal injection of pentobarbital sodium (50 mg/kg), with additional doses (12.5 mg/kg) given as needed. The mice were then placed on a custom Plexiglas tray and maintained at 37°C with a homeothermic blanket and a rectal temperature probe (FHC, Inc, Bowdoin, ME). The right carotid artery was isolated through a midline cervical incision, and an ultrasonic flow probe (Transonic Systems, Ithaca, NY) was used to monitor carotid blood flow. A 2-mm 2 piece of filter paper (Whatman #2, Maidstone, United Kingdom) saturated in 10% ferric chloride (Sigma-Aldrich) was applied to the surface of the carotid artery for 3 minutes; the vessel was then rinsed with isotonic saline, and carotid blood flow was monitored continuously until the onset of flow cessation (Ͼ1 minute) or 30 minutes. Carotid blood flow was expressed as a percentage of baseline values and analyzed at 10, 20, and 30 minutes. The investigators performing and analyzing thrombosis experiments remained blinded as to the mouse genotype.
Statistical Analysis
All data are expressed in a box plot with outliers identified as closed circles. Comparisons between individual groups were performed with nonparametric tests using GraphPad Prism software (GraphPad Software Inc, La Jolla, CA). Paired experiments were compared with Wilcoxon signed rank rests; for comparisons among multiple individual groups, probability values were adjusted with a Bonferroni step-down procedure as described previously 30 with SPSS software (IBM Corp). Unpaired 2-group experiments were performed with a Mann-Whitney U test. PՅ0.05 was considered statistically significant.
Results
Circulating Microparticles Contain Del-1
We tested for the presence of Del-1 on the surface of circulating peripheral blood microparticles with a murine monoclonal antibody to human Del-1 (D345) by flow cytometry. Del-1 was readily demonstrated on the surface of microparticles ( Figure 1A ). Prior treatment with the detergent Triton X-100 decreased the reactivity to Ͼ75%, which indicates that most of the signals were derived membrane-enclosed structures. 21 The microparticles were resolved according to the cell of origin (endothelial cell, monocyte, platelet, or red cell) based on expression of cell-specific markers. Del-1 was present in all populations; microparticles derived from red blood cells formed the major proportion of Del-1-containing microparticles (32Ϯ6%), followed by platelets (27Ϯ3%), monocytes (7Ϯ2%), and endothelium (5Ϯ1.2%; Figure 1B ). Furthermore, microparticle-bound Del-1 was detected in peripheral blood microparticles by immunoblotting with the monoclonal antibody D345 ( Figure 1C ).
Endothelial Cells Internalize Platelet Microparticles
Del-1 has been shown to be associated with the surface of endothelial cells. 16 We examined whether endothelial cells in culture secrete Del-1. To this end, the serum-free culture supernatant from HUVECs was examined by immunoblotting. A single band at 52 kDa was detected in the culture medium ( Figure 2) . Using an ELISA, we detected 2.6Ϯ2.8 ng/mL Del-1 in endothelial cell conditioned medium. In addition, we also measured 78Ϯ23 ng/mL in the plasma of healthy individuals, presumably derived from endothelium. To determine whether endothelium can internalize platelet microparticles, we isolated platelet microparticles and endosomes from washed human platelets (Figure 3 ). Endothelial cells were incubated with BODIPY-labeled platelet microparticles, and morphological evidence of uptake was obtained by confocal fluorescence microscopy. To distinguish between cell-surface binding and actual internalization, extracellular and cell-surface fluorescence was quenched by addition of trypan blue (0.4 mg/mL), and the unquenched fluorescence, which represented the internalized microparticles, was examined for cytoplasmic fluorescence. 31 Platelet microparticles were avidly engulfed by the endothelial cells ( Figures 4A and 4B) . Initially, the microparticles were distributed diffusely throughout the cytoplasm. Within 15 minutes, the microparticles were localized predominantly to the periphery, to 1 pole of the cells. Uptake was complete within the time interval of 30 minutes. Virtually no internalization was seen at 4°C. We quantified the internalization of BODIPY-labeled platelet microparticles by measuring the cytoplasmic fluorescence associated with endothelial cells by flow cytometry after quenching the cell-surface fluorescence with trypan blue. Uptake was dependent on the amount of microparticles added ( Figure 5 ). In HUVECs (Figure 6A ), the monoclonal antibody to Del-1 inhibited uptake compared with the buffer control (2.5Ϯ0.6 versus 3.6Ϯ1.0; adjusted Pϭ0.027, nϭ9); under similar conditions, an irrelevant control monoclonal antibody had no significant effect (3.3Ϯ0.8 versus 3.6Ϯ1.0; adjusted Pϭ0.027, nϭ9). In human microvascular endothelial cells (Figure 6D ), the Del-1 antibody also inhibited uptake (2.8Ϯ0.6 versus 5.4Ϯ0.5; adjusted Pϭ0.02, nϭ9). Because Del-1 has the integrin-binding RGD motif, we examined the effect of Del-1) . Serum-free medium from cultured human umbilical vein endothelial cells was subjected to SDS-PAGE followed by immunoblotting with the anti-Del-1 antibody D345 as in Figure 1. A B Figures 6A and 6D ). The effects of annexin A5 and abciximab were not additive. Accordingly, these results show the phosphatidylserine-and integrin-mediated uptake of microparticles by the endothelium. The Del-1-dependent uptake was not restricted to platelet microparticles. Phosphatidylserine-expressing microparticles from red blood cells are also endocytosed in a Del-1-and integrindependent manner ( Figure 6C ). In contrast, under similar conditions, the uptake of labeled exosomes was not inhibited by Del-1 antibody ( Figure 6B ). To characterize the uptake pathway, we incubated HUVECs for 30 minutes with compounds that inhibit particle uptake, namely, chlorpromazine, which inhibits clathrindependent endocytosis, or amiloride to block macropinocytosis. Chlorpromazine (10 mol/L) decreased the intracellular content of labeled vesicles compared with the buffer (1.17Ϯ0.4 versus 3.6Ϯ1.0; adjusted Pϭ0.027, nϭ9), whereas under similar conditions, amiloride caused a slight decrease ( Figure 6A) . Thus, the clathrin-dependent endocytotic process plays a predominant role in the uptake process.
Del-1-Deficient Mice Have Defective Uptake of Platelet Microparticles by Endothelial Cells In Vivo
To assess the in vivo significance, we infused labeled platelet microparticles into the inferior vena cava of anesthetized mice. After 5 minutes, the mice were euthanized, and endothelial cells from lung, liver, and spleen were isolated and examined by flow cytometry. We compared the cytoplasmic fluorescence of endothelial cells from Del-1-deficient mice to the fluorescence in endothelial cells from their wild-type littermate controls, which were subjected to the same experimental procedure simultaneously (Figure 7 ). Del-1-deficient mice had significantly less fluorescence than wild-type mice in pulmonary endothelial cells (1.09Ϯ1.3% versus 3.0Ϯ2.0%; Pϭ0.02, nϭ9) and in liver endothelial cells in 9 separate pairs of experiments (2.85Ϯ1.1 versus 1.35Ϯ0.9; Pϭ0.01, nϭ9). There was no significant difference in uptake by splenic endothelial cells. These experiments show that Del deficiency leads to impaired uptake of microparticles by lung and liver endothelial cells in vivo.
Increased Circulating Microparticles After LPS Administration in Del-1-Deficient Mice
Del-1-deficient mice have normal levels of microparticles compared with their wild-type littermate controls. Endotoxemia induces increased microparticles in the blood in human and in mice. 32 ,33 Hence, we tested the effect of LPS administration on the level of circulating microparticles in Del-1-deficient mice and their littermate controls. As seen in Figure 8 , LPS induced significantly higher levels of microparticles in Del-1-deficient mice (Pϭ0.02, nϭ9) than in their wild-type littermate controls when measured 6 hours after administration.
In spite of the increased microparticles, when tested in a carotid artery injury/thrombosis model, no significant differ- 
Discussion
Circulating microparticles were first described in 1967 as platelet membrane fragments detected in human plasma. 34 Although initially considered as cell debris, a central role in hemostasis has been identified for platelet microparticles. 2, 35 Microparticles from different cells have been identified in the circulating blood. 36 Despite their physicochemical characterization, very little is known about the fate of microparticles in the circulation. Phosphatidylserine-expressing platelet microparticles have a short half-life of Ͻ10 minutes when infused, which implies that microparticles are continuously formed in the circulation. 37 The mechanism of clearance of platelet microparticles from the circulation is not well understood; some clues may be obtained from studies on the clearance of phospholipid liposomes, which have been used extensively as vehicles for drug delivery. 38 The clearance of liposomes is affected markedly by the lipid composition of the liposomes; phosphatidylserine markedly enhances the clearance rate of liposomes. Even in intact red blood cells, incorporation of as little as 3% mol of phosphatidylserine in the outer leaflet results in rapid clearance. 39 The present experiments show that Del-1 secreted by the endothelium plays a role in the clearance of phosphatidylserine-expressing microparticles. Del-1 has been demonstrated on the endothelial cell surface, and we have detected 78Ϯ23 ng/mL Del-1 in the plasma of healthy control subjects, presumably derived from endothelium. The endothelium presents a very large surface, estimated at Ϸ320 mol/L 2 , 40 and it is constantly in contact with flowing blood. The microparticles, because of their size relative to other formed elements in the blood, circulate in the periphery and are poised to interact with endothelial cells efficiently. When infused into the inferior vena cava, the microparticles encounter the pulmonary endothelium immediately, and the present data show that pulmonary endothelial cells contain internalized microparticles. Del-1, via its integrin-and phosphatidylserine-binding domains, acts as anchor for the uptake. Del-1-deficient lung and liver endothelial cells displayed significantly impaired uptake of platelet-derived microparticles. However, there were no significant differences in uptake by wild-type and Del-1 Ϫ/Ϫ splenic endothelial cells. Spleen has a unique open circulation designed to filter particles, and splenic endothelial cells are endowed with phagocytic functions. 41 Furthermore, spleen is rich in lactadherin, a Del-1 homologue, which may substitute for Del-1. The number of circulating microparticles is increased after splenectomy. 22 Exosomes are 40-to 100-nm membrane vesicles secreted by most cell types that contain proteins involved in membrane transport or vesicle biogenesis, as well as different heat shock proteins, tetraspanins, and integrins. 42 Platelets release exosomes on activation, 23 and platelet-derived exosomes can modulate endothelial cell functions under certain experimental conditions. 43 However, exosomes do not express phosphatidylserine on their surface, 23 which is consistent with the fact that the Del-1 antibody does not inhibit their uptake by endothelium. Activated platelets and endothelial cells also generate a significant proportion of microparticles that do not express phosphatidylserine, 44, 45 and the clearance of these microparticles will be Del-1 independent.
The uptake of microparticles by the endothelium mainly involves the clathrin-dependent endocytotic pathway, because chlorpromazine inhibited this process to 20%, whereas amiloride (an inhibitor of micropinocytosis) did not significantly decrease uptake. These data suggest that the clathrindependent endocytotic pathway plays a major role in uptake. Because microparticles are heterogeneous in size and in the expression of surface markers, depending on the cells of origin, it is likely that multiple distinct pathways are engaged in their uptake.
Antibodies to Del-1 inhibit microparticle uptake only in part, and Del-1-deficient mice have normal levels of microparticles under baseline conditions. Furthermore, in a carotid artery injury model, we could not demonstrate a hypercoagulable state despite an increase in microparticles. The phosphatidylserine-dependent phagocytic process is also involved in clearance of apoptotic cells 46 and plays a vital role in organogenesis and tissue remodeling. For important homeostatic mechanisms, redundant mechanisms or parallel systems must necessarily exist. Therefore, it will not be surprising to find other mediators, which can compensate in part for Del-1 deficiency. Several phosphatidylserinebinding molecules, such as ␤2-glycoprotein I 47 and lactadherin, 48 are associated with circulating microvesicles. In fact, multiple phosphatidylserine-dependent phagocytic receptors that mediate clearance of phosphatidylserineexpressing apoptotic cells have been identified on macrophages. 49 Many of these receptors and opsonins are also present in endothelial cells and may play a role in the clearance of microparticles. Thus, Del-1 deficiency may contribute to the procoagulant state only at times of pathological increases in microparticle generation.
In summary, we have identified Del-1 as one of the mediators of microparticle clearance in vivo.
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